CytoDyn Retains Gibraltar Associates for Corporate and Investor Communications

LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the "Company") (CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has retained Gibraltar Associates for corporate communications and investor relations services. Gibraltar will offer integrated consulting services to highlight CytoDyn’s development of monoclonal antibody therapies for the treatment of HIV and other infectious diseases, as well as increase the Company's visibility with the institutional investor community.